Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adalimumab eow or ew · 1 trial · 1 indication
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
| Arm | Type | Description |
|---|---|---|
| Adalimumab 40 mg every other week or every week | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Adalimumab 40 mg eow or ew | BIOLOGICAL | Adalimumab 40 mg by subcutaneous injection every other week or every week |
Inclusion Criteria: * Participant had completed the Year 1 of Study M02-433 (NCT00055497) * Diagnosis of Crohn's disease * Willing and able to give informed consent Exclusion Criteria: * Diagnosis of ulcerative colitis * Pregnancy or breastfeeding * Previous use of infliximab or other anti-TNF (t...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE3 | Duvakitug, Brivekimig |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
Adalimumab eow or ew is used for the treatment of Crohn's Disease, a chronic inflammatory condition of the gastrointestinal tract. It is a monoclonal antibody therapy being studied in a Phase 3 clinical trial. The dosing abbreviation eow or ew refers to every other week or every week administration schedules.
Adalimumab eow or ew targets TNF, also known as tumor necrosis factor. It is an inhibitor of TNF, a pro-inflammatory cytokine involved in Crohn's Disease. By inhibiting TNF, the drug aims to reduce inflammation in the gastrointestinal tract.
Adalimumab eow or ew is being developed by Abbott Laboratories, which trades under the ticker symbol ABT. Abbott Laboratories is a global healthcare company involved in the research and development of pharmaceutical products.
Adalimumab eow or ew is in Phase 3 clinical development for Crohn's Disease. It is an investigational therapy and has not been approved by the FDA for this indication. The Phase 3 trial has been completed.
Adalimumab eow or ew has been studied in one Phase 3 clinical trial, NCT01070303, titled Remission in Subjects With Crohn's Disease, Open Label Extension. This trial enrolled 177 participants, was conducted in the United States, and has been completed. It was an open-label, uncontrolled study.